Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer deaths worldwide. Despite the high incidence of HCC, mortality remains high, with an estimated 5-year survival rate of less than 20%. Surgical resection represents a potential curative treatment for HCC; however, less than 20% of patients with HCC are candidates for surgical resection. In patients with unresectable HCC, Yttrium-90 (Y90) transarterial radioembolization (TARE) has emerged as an innovative treatment option. This locoregional therapy delivers high doses of radiation directly to liver tumors via intra-arterial injection, allowing for the targeted destruction of malignant cells while sparing surrounding healthy tissue. In this review, we will explore the latest advances in Y90 TARE for the treatment of HCC, focusing on key developments such as the following: (1) improvements in radiation lobectomy and segmentectomy techniques, (2) the introduction of personalized dosimetry, (3) the integration of combination therapies, (4) the use of imageable microspheres, (5) pressure-enabled Y90 delivery systems, and (6) the application of Y90 surrogates.
肝细胞癌（HCC）是全球癌症死亡的第四大原因。尽管HCC发病率高，其死亡率仍居高不下，预计五年生存率低于20%。手术切除是HCC的潜在根治性治疗手段，但仅有不到20%的HCC患者适合接受手术切除。对于不可切除的HCC患者，钇-90（Y90）经动脉放射栓塞术（TARE）已成为一种创新的治疗选择。这种局部区域疗法通过动脉内注射将高剂量辐射直接输送至肝脏肿瘤，在靶向破坏恶性细胞的同时保护周围健康组织。本综述将探讨Y90 TARE治疗HCC的最新进展，重点关注以下关键发展方向：（1）放射肝叶切除术与肝段切除术的技术改进，（2）个体化剂量学的应用，（3）联合治疗方案的整合，（4）可视化微球的使用，（5）压力驱动型Y90输送系统，以及（6）Y90替代物的应用。
Advances and Emerging Techniques in Y-90 Radioembolization for Hepatocellular Carcinoma
肿瘤(癌症)患者之家